Saturday, 25 May 2024
Friday, 05 Jan 2024 12:00 am

Upstream Bioprocessing Market is expected to reach US$ 25,046.69 million by 2030

Global upstream bioprocessing market size is predicted to reach USD 25,046.69 million by 2030 from USD 9,174.09 million in 2022| Latest Facts and Developments

By The Insight Partners

Bioreactors/Fermenters Segment to Dominate Upstream Bioprocessing Market Based on Product Type During 2022–2030

According to our new research study on "Upstream Bioprocessing Market Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis," the market value is projected to grow from US$ 9,174.09 million in 2022 to US$ 25,046.69 million by 2030. The upstream bioprocessing market is further anticipated to record a CAGR of 13.4% from 2022 to 2030. Key factors driving the upstream bioprocessing market growth include the commercial use of single-use bioreactors, outsourcing of biopharmaceutical manufacturing, and rapid growth of pharmaceutical and biotechnology industries. However, a stringent regulatory framework hinders market growth.

Various manufacturers are developing single-use bioreactors (SUBs) due to their robust build and high performance, which are necessary for the commercial manufacturing of biopharmaceuticals. Incorporating technologies associated with biofilm formation, stirring mechanisms, bioreactor designs, and sensor systems, among others, have increased the adoption of disposable reactors at the laboratory and production scales. Single-use bioreactors are operated to manufacture next-generation cell and gene therapies, and they are suitable for continuous bioprocessing. Advancements in cell-culture processes now enable the development of higher titers and cell densities, which indicate a large scope for the adoption of SUBs. Single-use bioreactors operate with a low risk of contamination, shorter production turnaround times, and reduced validation time. In the last few years, the use of single-use bioreactors has increased in modern biopharmaceutical processes owing to their unique ability to aid enhanced flexibility, reduce investments, and limit operational costs. Also, many companies have developed single-use bioreactors for producing a wide range of therapeutics. In March 2021, Thermo Fischer Scientific launched the HyPerforma DynaDrive single-use bioreactors with 3,000 L and 5,000 L capacities. Sartorius AG offers a wide range of single-use bioreactors. The company provides ambr 15 for a 10–15 mL micro bioreactor scale and Biostat STR for 50–2,000L. The use of single-use bioreactors is subsequently increasing in upstream bioprocessing. Thus, the increasing acceptance of single-use bioreactors for the production of therapeutics propels the upstream bioprocessing market.

Upstream Bioprocessing Market, by Region, 2022 (%)

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/brochure/TIPRE00006819

Source: The Insight Partners Analysis

Many contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) engage in bioprocessing activities, which triggers the demand for bioreactors in these facilities. The strategic outsourcing of pharmaceutical manufacturing through bioprocessing allows biopharmaceutical companies to leverage external partners' expertise and advanced capabilities in upstream processes, facilitating access to specialized technologies, process optimization expertise, and scalable manufacturing capacity. By partnering with CDMOs and CMOs, biopharmaceutical firms can efficiently manage manufacturing needs, accommodate fluctuations in production demands, and focus on core research and development activities. Additionally, outsourcing offers cost efficiencies and risk mitigation by leveraging external partners' established infrastructure and regulatory-compliant facilities. Outsourcing the bioprocessing functions allows biopharmaceutical companies to focus on fostering innovation, technological advancements, and overall upstream process expansion. Thus, outsourcing biopharmaceutical manufacturing significantly drives the growth of the upstream bioprocessing market.

Thermo Fisher Scientific Inc; Esco Micro Pte Ltd; Cellexus International Ltd; Sartorius AG; Danaher Corp; Getinge AB; Merck KGaA; PBS Biotech, Inc.; Corning Inc; and Entegris., and PBS Biotech Inc are among the key companies operating in the upstream bioprocessing market. The companies have been implementing organic strategies (such as product launches and product approvals) and inorganic strategies (such as expansions, collaborations, and partnerships) to secure growth in the market. For instance, in December 2023, Merck acquired Erbi Biosystems, a Massachusetts-based company that developed the "Breez" 2 ml micro-bioreactor platform technology. The purchase boosts Merck's upstream therapeutic protein portfolio, enabling it to promptly develop lab-scale protocols for scalable cell-based perfusion bioreactor processes with capacities ranging from 2 ml to 2000 l. Additionally, it offers opportunities for further study and advancement in cutting-edge modality applications, like cell therapies. 

The report segments the upstream bioprocessing market as follows:

Based on product type, the upstream bioprocessing market is segmented into bioreactors and fermenters, cell culture media, filters, bags and containers, and others. The bioreactors/fermenters segment held the largest share of the market in 2022. The cell culture segment is anticipated to register a significant CAGR in the upstream bioprocessing market during 2022–2030. Bioreactors and fermenters serve as core vessels in which cells and microorganisms are grown for various therapeutic and bioprocessing applications, involving the expression and production of biologically derived compounds. These systems are engineered to provide an optimal environment for cell growth, incorporating precise control over parameters such as temperature, pH, dissolved oxygen, and agitation. These are critical for cultivating cells and microorganisms in large-scale bioprocessing operations.

Based on workflow, the upstream bioprocessing market is classified into media preparation, cell culture, and cell separation. The cell separation segment held the largest share of the market in 2022. It is further anticipated to record a significant CAGR in the upstream bioprocessing market from 2022 to 2030. Cell separation is the initial stage of segregating protein products (cells) from the culture. The amount and quality of the product collected in bioreactors would determine whether to terminate the cell culture, which is an important decision.

Based on usage type, the global upstream bioprocessing market is classified into single use and multiuse. The single use segment held a larger share of the market in 2022. The upstream bioprocessing market for this segment is expected to grow at a significant CAGR during 2022–2030. The upstream bioprocessing market has experienced a transformative shift with the widespread adoption of single-use technologies. Single-use systems, including bioreactors, bags, and connectors, have gained prominence for their flexibility, cost-effectiveness, and reduced risk of cross-contamination. These disposable components replace traditional stainless-steel equipment, offering a more agile and scalable approach to bioproduction. The single-use trend accelerates process development, minimizes cleaning and validation efforts, and facilitates quick changeovers between production runs.

The upstream bioprocessing market, by mode, is segmented into in-house and outsourced. In 2022, the in-house segment held a larger market share. The outsourced segment is expected to record a higher CAGR in the upstream bioprocessing market during 2022–2030. In-house manufacturing is gaining traction in the upstream bioprocessing market as biopharmaceutical companies seek greater control over their production processes. Establishing in-house upstream bioprocessing facilities enables companies to tailor processes to their needs, ensuring a more customized and efficient approach. This move often involves investment in state-of-the-art bioreactors, cell culture systems, and associated technologies.

In terms of geography, the upstream bioprocessing market is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

The Insight Partners :    https://www.theinsightpartners.com

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
© The News and Media Division of The Insight Partners 2024 | All Rights Reserved | Privacy Policy